Introduction
============

Advances in genomics and informatics have validated the importance of individuality in cancer diagnosis and treatment. Evidence illustrates that cancer is a disease of genetic and epigenetic causality, profoundly affected by environment and lifestyle [@B1]. An increasing number of genetic alterations have been characterized that drive the pathogenesis of cancer and convey therapeutic actionability [@B2]. These driver mutations often are not restricted to a specific cancer type, histology or patient demographic. This unprecedented molecular understanding of individual cancers has ushered in a new era of health care coined precision medicine [@B3].

Precision medicine has begun a reprogramming of clinical oncology practice [@B4], [@B5]. Specialization in organ-oriented disease is being supplemented with molecular target assessment and targeted treatment across cancer types [@B6]-[@B9]. New clinical trial models (e.g., BASKET trial, NCI-MATCH) emphasize treatment decisions based on druggability of gene mutations rather than tumor histology [@B10], [@B11]. Precision medicine consortia have formed to test this new mode of cancer management [@B12]. The Precision Medicine Exchange Consortium (PMEC) is one such consortium, consisting of eight major cancer centers in the US, including the Wake Forest Baptist Comprehensive Cancer Center (WFBCCC).

To investigate the relationship between precision medicine-derived cancer genomic correlates and patient demographics at WFBCCC, 431 cancer patients were enrolled into the Wake Forest Precision Oncology Initiative trial. This patient cohort reflects the patient population in the WFBCCC catchment area with a high representation of tobacco-related cancers (e.g., lung, colorectal, and bladder) and African American (AA) ancestry (13.5%). In the WFBCCC catchment area, (22% of adults are current tobacco users versus 19% nationally). Cigarette smoke is a known carcinogen, causing defined mutational signatures [@B13], [@B14]. However, smoking-related genetic changes in cancer are not well-characterized. Even more unclear is whether the mutational events differ between AA and Caucasian cancer patients, despite AA cancer patients having a poorer prognosis, including cancer-related and higher overall mortality rates [@B15].

Here, we report the characterization of the mutational landscapes of our unique cohort of cancer patients with findings validated in The Cancer Genome Atlas (TCGA) dataset. We also provide examples of mutation directed treatment in these patients to demonstrate the clinical impact of precision oncology initiatives.

Material and Methods
====================

Patient Cohort
--------------

Four hundred thirty-one cancer patients from the catchment area of the WFBCCC participated in the IRB-approved Wake Forest Precision Oncology Initiative (POI) from March 1, 2015 to May 30, 2016. African American status is based on self-reported ancestry. Each patient was consented for research analysis of sequencing results. Tumor specimens were evaluated by two board-certified pathologists to confirm diagnosis and classification. Tumor biopsies and surgical specimens were formalin-fixed and paraffin-embedded immediately following acquisition, according to standard clinical protocol. Tumor blocks of sufficient cellularity (\>20%) and limited necrosis were selected and submitted to Foundation Medicine for FoundationOne® testing. The clinical management process is shown in Figure [S1](#SM1){ref-type="supplementary-material"} and supplementary methods. ClinicalTrials.gov Identifier**:**NCT02566421

Genomic Profiling
-----------------

Tumor tissue was subjected to Next Generation Sequencing (NGS) to identify mutations, rearrangements and copy number alterations spanning 415 cancer-related genes that make up the FoundationOne ® (F1) test (Foundation Medicine, Cambridge, MA) (Supplementary Methods) [@B16].

Statistical and Bioinformatic Analysis
--------------------------------------

Nonsynonymous somatic mutation calls were quantified. Patients were assigned to low or high mutation load groups based on the cohort mean mutation number. Fisher\'s exact test and Benjamini-Hochberg multiple testing adjustments were used to determine associations between mutation load and DNA damage genes and chromatin remodeling genes. Smoking status was defined by self-reported smoking history obtained from Cancer Registry and/or Epic Electronic Medical Record. Never smokers were defined as respondents who smoked less than 100 cigarettes in their lifetime. Based on evidence that smoking cessation reduces cancer risk by half at five years, active smokers at the time of clinical data collection and those who had quit smoking within the previous five years were considered current/recent smokers [@B17], [@B18]. Those having quit more than five years prior to data collection were defined as former smokers. Only white (Caucasian) and black (AA patients) were included in disparities analyses, as these are the two main ethnic groups of the WFBCCC catchment area. Other racial/ethnic populations were underrepresented in the sample (less than 5%). Analyses for discovery of smoking-related mutations focused on genes with functional roles in DNA Damage Repair and Chromatin Remodeling. Each set of analyses used the Cochran-Mantel- Haenszel test to uncover associations between smoking status (defined as an ordinal variable - Never, Former, Recent) and gene mutation. Fisher\'s exact test was used to assess significance (p \< 0.05) of gene mutation frequencies that differed with respect to low and high mutation load and racial status (Caucasians versus AA). The Hochberg (1988) approach was used to adjust for multiple testing [@B19]. MutSig algorithm, MutSigCV, was used to evaluate the significance of mutated genes. All analyses were performed with R statistical computing software version 3.3.0 [@B20]. Mutagenic processes and tumor clonality were analyzed with R packages somaticSignatures and SciClone, respectively (Supplementary Methods) [@B21].

Results
=======

Mutational Analysis
-------------------

We analyzed 431 cancer patients from the catchment area of the WFBCCC that participated in the IRB-approved Wake Forest Precision Oncology Initiative (POI). Patient demographics are summarized in Table [1](#T1){ref-type="table"}, Table [S1](#SM1){ref-type="supplementary-material"} and Figure [1](#F1){ref-type="fig"}. In our patients, the most frequently mutated genes were tumor suppressor genes *TP53, APC, FAT1, RB1, BRCA2*, and *NF1*; Wnt signaling pathway genes *LRP1B* and *APC*; oncogenes *KRAS, PIK3A*, DNA damage repair (DDR) genes (*ATM, BRCA2*); chromosomal integrity genes (*TERT*), and chromatin remodeling (CR) genes (*KMT2D or MLL2, KMT2C or MLL3, ARID1A, ARID1B, EP300*) (Figure [2](#F2){ref-type="fig"}A).

Some of the observed gene mutations were expected. For example, *TP53* showed a uniformly high frequency of mutation across all cancer types while *APC* was predominantly mutated in colorectal cancer. *KRAS* was mutated at high frequency in pancreatic, colorectal, and lung cancer. *LRP1B* was frequently mutated only in lung cancer (43 of 90, 47.8%). Another gene highly mutated in lung cancer was *SPTA1*(33 of 90, 37%) that has unknown oncogenic functions. Analysis of The Cancer Genome Atlas (TCGA) lung cancer cohort (adenocarcinomas and squamous) validated the frequent mutation of *SPTA1* gene (Figure [S2](#SM1){ref-type="supplementary-material"}). *EPHA3* and *EPHA5* were also frequently mutated in both our and TCGA cohorts (Figure [S2](#SM1){ref-type="supplementary-material"}). *TERT*, which codes for telomerase and is involved in the longevity of tumor cells, was found to be frequently mutated at a promoter hot spot (-124C \> T) in brain tumors (16 of 31, 53%), bladder cancers (9 of 16, 56%), and head/neck cancers (6 of 26, 23%), consistent with recent reports [@B22], [@B23]. In contrast, the *TERT* promoter is rarely mutated in colorectal, lung or pancreatic cancer, or soft tissue sarcoma (Figure [2](#F2){ref-type="fig"}B).

A striking observation was the remarkably high mutation rates of DDR and CR genes in our cohort and their association with high-mutational load (Figure [3](#F3){ref-type="fig"}A, B, C), underscoring the highly unstable genome associated with smoking-related cancers that dominate our cohort.

Large numbers of gene mutations (hypermutation phenotype) and copy number alterations (chromosomal instability or CIN) represent two different types of genomic instability [@B24]. We observed that the CIN phenotype exhibited variable patterns in different cancer types, with extensive overall changes in lung and colorectal cancers (Figure [S3](#SM1){ref-type="supplementary-material"}A). Despite high mutation rates, two smoking-related cancer types, bladder and head/neck cancers, did not show extensive copy number alterations (Figure [3](#F3){ref-type="fig"}C, Figure [S3](#SM1){ref-type="supplementary-material"}A). Among the most extensively amplified genes were oncogenes, including *ERRB2, MYC, MET, CDK6*, and *EGFR* (e Figure [3](#F3){ref-type="fig"}B). Two cases exhibited amplification of immunosuppressing genes *PD-L1* (*CD274*) and *PD-L2 (PDCD1LG2)*, suggesting a role for anti-PD-1 or anti-PD-L1 therapy. Genes frequently deleted in our advanced cancer cohort are *CDKN2A/B* and *PTEN* (Figure [S3](#SM1){ref-type="supplementary-material"}B).

Gene Mutations Associated with Smoking
--------------------------------------

In our cohort, proportions of smokers were similar in AAs and Caucasian-Americans (38 of 58, 216 of 356, respectively; Fisher exact test p-value, 0.56). Current/recent smokers exhibited a significantly higher mutational load (mean = 20.5, median = 14.0) than former smokers (mean = 13.0, median = 11.5; p = 0.017, 2-sided t-test) and never smokers (mean = 12.3, median = 11.0; p = 0.029, 2-sided t-test). Analysis of total mutations per cancer showed a heterogeneous pattern (Figure [S4](#SM1){ref-type="supplementary-material"}) with lung, bladder, and colorectal cancer exhibiting high tumor mutational load. Appendiceal, brain, and prostate cancers exhibited the lowest mutational load.

Analysis of the mutational signatures characterized by nucleotide changes in the context of neighboring nucleotides identified three major signatures (Figure [4](#F4){ref-type="fig"}A). Current smokers, former smokers and never smokers exhibited distinct mutational signatures (Figure [4](#F4){ref-type="fig"}B). Many DDR and CR genes exhibited associations with smoking status (Figure [4](#F4){ref-type="fig"}C), with a greater frequency of mutation in current/recent or former smokers as compared to never smokers. After adjusting for multiple testing, mutations in two DDR genes - *CDK12* and *BRCA2* met the criteria for statistical significance (p = 0.0069 and 0.016, respectively). Similarly, the CR gene *KMT2D* met the criteria for statistical significance (p = 0.0087), while two others (*KDM6A* and *SMARCA4*) were nominally significant (p = 0.026 and 0.032, respectively) (Figure [4](#F4){ref-type="fig"}C, Table [S2](#SM1){ref-type="supplementary-material"}).

To begin validation in the TCGA cohort we found that among the solid tumors, mutation and smoking status data was available in 2,821 cases. As shown in Figure [4](#F4){ref-type="fig"}D, current and former smokers have similar mutation frequencies of these genes. This analysis showed that most smoking-related gene mutations found in our cohort (e.g., *KMT2D, BRCA2*) were validated in the TCGA cohort.

Intratumoral clonal heterogeneity poses serious challenges to precision oncology treatment [@B25]. Tumors comprised of multiple clones with different mutational events may require multiple targeting strategies; in combination or in sequence. We quantified tumor clonal heterogeneity based on clustering of variant allele fractions (Figure [S5](#SM1){ref-type="supplementary-material"}A, B, see Methods). Mutation rates for 48% of patients were relatively low with no clonal diversity. For the others, 19, 23, and 10% of cases exhibited 1, 2 or more than 2 clones, respectively, based on clonality analysis (Figure [S5](#SM1){ref-type="supplementary-material"}C). Higher clonality was associated with smoking (Figure [4](#F4){ref-type="fig"}E).

Gene Mutations Associated with Race
-----------------------------------

The overall mutational landscape of AA patients is similar to that of the whole WFBCCC cohort, the majority of which are Caucasian patients (Figure [5](#F5){ref-type="fig"}A and Figure [2](#F2){ref-type="fig"}A). However, our analysis revealed differential mutation rates in the key genes, *TP53* and *KMT2C* (Figure [5](#F5){ref-type="fig"}B). In the TCGA cohort, there are 842 AA and 7,149 Caucasian cases with mutation data and 892 AA and 7,679 Caucasians with gene amplification data. *TP53* (p = 0.027), and to a lesser extent, *KMT2C* (p = 0.093), were more frequently mutated in AA patients in the TCGA cohort (Figure [5](#F5){ref-type="fig"}C). Gene copy number analysis revealed marked differences in five oncogenes in our cohort (Figure [5](#F5){ref-type="fig"}D); all of them were found to be more significantly amplified in AA in the TCGA cohort (Figure [5](#F5){ref-type="fig"}E).

Precision Oncology Case Reports
-------------------------------

The essence of precision oncology is to match mutational information with drugs that have shown therapeutic efficacy in targeting the mutated protein. Oncologists at WFBCCC have designed clinical treatment regimens based on genomics testing in our Precision Oncology Trial and patients have shown remarkable responses. Key examples are described in [Supplementary Material](#SM1){ref-type="supplementary-material"}.

Discussion
==========

Smokers and AAs are more prevalent among our disproportionately rural, Appalachian/Piedmont catchment area population. Thus, we are able to uniquely interrogate mutations associated with these two understudied populations. This undertaking has provided a number of insights. Among the most interesting discoveries are the revelations that DDR and CR genes are highly mutated in current/former smokers, and smoking is associated with augmented clonal evolution (clonality) and tumor heterogeneities. This is consistent with recent genomic characterization of smoking related cancers [@B26]. These results provide strong evidence that genomic instability is a fundamental hallmark of cancer and the events underlying the regulation of genome stability are centered on interactions with environmental factors and lifestyle.

AA cancer patients have a more dismal prognosis, which represents a key health disparity challenge in the US. Our genomics analysis revealed a number of genes mutated at different frequencies in AA and Caucasian cancer patients. After further analysis of the larger independent TCGA cohort, mutations of the tumor suppressor gene *TP53* still emerged as a more common event in AA cancer patients. Notably, in our cohort of lung cancer, mutation rates for a number of genes including *TP53* are higher than that observed in the TCGA cohort, consistent with the predominance of advanced and smoking-related cancers in our cohort. However, our analysis showed that the enriched mutation in *TP53* in AA is not driven by lung cancer in the cohort because *TP53* mutation rates are similar in AA and Caucasian Americans (p = 0.5). TP53 has long been recognized as a critical control gene for genome stability [@B27]. Numerous studies have shown that mutations of *TP53* are associated with poor prognosis in cancer [@B28]. Therefore, genomic stability regulated by TP53 may be a key factor that contributes to cancer outcome disparities among different racial groups. The limitation of this study is the size of cohort enrolled in precision oncology initiatives due to the enrollment criteria and cost associated with the clinical sequencing tests. Therefore, future data sharing effort will enable pooled analysis of all the major precision oncology programs in the country to determine whether genetic events such as increased TP53 mutation rates are observed in all major cancer types and their relationship with smoking. Interestingly, during the review of our study, a recent paper focusing on lung cancer reported overall similar mutation frequencies between AA and Caucasian American, however they also observed more prevalent *TP53* mutation in AA subgroup than Caucasian group [@B29].

In addition to gaining insight into the knowledge of genetic/molecular mechanisms of cancer development/progression, a key benchmark for precision oncology initiatives is the translatability of genomics information to more accurately targeted and beneficial treatments in patients [@B5], [@B30]-[@B33]. Several successful examples at WFBCCC are reported here and described in supplemental document.

There is no doubt that increasing numbers of cancer patients will benefit from the precision oncology design. There are, however, a number of important challenges and limitations [@B34].

First, the current precision oncology initiatives focus more on advanced metastatic cancer patients. Many of these patients die within 3-4 months of the genomic testing, before treatment decisions can be rendered. Thus, genomic testing should extend to patients with newly diagnosed metastatic disease, with the hypothesis that a patient with longer expected survival will benefit more from precision treatment. Retesting of tumors from recurrent patients will identify treatment-associated mutations to revise therapeutic strategies. Secondly, drug availability is a major problem [@B35]-[@B37]. Many FDA approved but off-label drugs, are not covered by insurance. Getting access to these off-label drugs on a compassionate basis invariably requires the resources and extra time of physicians. There clearly is a need for a streamlined process of drug acquisition for precision oncology to reach its full potential. Thirdly, genomic testing reveals many gene mutations without information about whether these mutations are deleterious (driver mutations). Thus, there is a clear need for efficient high throughput laboratory assays to identify functional mutations [@B38]. Fourthly, intratumoral heterogeneity poses a significant obstacle for sustained treatment response to a single agent therapy [@B25], [@B39]. Our clonality analyses showed that different clones exist in a fraction of tumors with different potential driver mutations. Therefore, precision oncology requires an understanding of tumor clonality to inform the design of combination or sequential therapy with different drugs. Finally, from the patients\' perspective, these complexities are compounded by the psychosocial and ethical considerations inherent to the genomic profiling process [@B40], [@B41]. In this newly evolving paradigm, patients and providers need to navigate care from a patient-centered framework. In the decision making process, smoking status and ethnicity should clearly be considered because of the association with differential mutation rates.

We thank the physicians and nurses who participated in the POI. We thank the patients who provided consent to participate in the POI knowing they may not directly derive benefit.

Funding
=======

The work is partially supported by the Cancer Center Support Grant from the National Cancer Institute to the Comprehensive Cancer Center of Wake Forest Baptist Medical Center (P30 CA012197) and funding for the Genome Data Analysis Centers from the National Institutes of Health (U24 CA143835 to I.S. and W.Z.). W.Z. is supported by Hanes and Willis Professorship in Cancer and a Fellowship by the National Foundation for Cancer Research. B.P. is supported by Charles L. Spurr Professorship of Medicine.

Supplementary Material {#SM0}
======================

###### 

Supplementary figures and tables.

###### 

Click here for additional data file.

![**Patient Demographics**. (A) Patient smoking status within the context of type of cancer. (B) Patient race as described within cancer type. (C). Gender of patients within each cancer type.](thnov07p2914g001){#F1}

![**Global Landscape of Somatic Mutations**. (A) Global somatic mutational landscape of all patients for the top 30 genes having the largest fraction of mutations. Top and left bar charts show the number of mutations and percent of mutated samples, respectively. The lower part of panel A summarizes clinical information from each patient. (B) Somatic mutational landscape for major cancer groups for the same 30 genes seen in (A). Cancer group-wise mutational patterns show large similarities (*TP53*) but also striking differences (*KRAS, APC, TERT*) between cancer groups.](thnov07p2914g002){#F2}

![**Associations between DDR/CR Gene Mutation Frequency, Tumor Mutational Load and Smoking Status.**DDR and CR genes are mutated at higher frequency (A) and in tumors with higher mutation load (B). High and low mutational load (ML) designations are based on above-mean (orange) and below-mean (light green) mutation count, respectively. Nonsynonymous protein-altering mutations (SNVs, in/dels, rearrangements) and copy number deletions were included. \*\*\*\* (p \< 0.0001); \*\*\* (p \< 0.001); \*\* (p \< 0.01); \* (p \< 0.05), Fisher\'s exact test and Benjamini-Hochberg adjusting. (C) Mutational load across cancer groups as a function of smoking status. Boxes mark the interquartile range (25^th^-75^th^ percentile) of the distribution while the whiskers demarcate the 5^th^ and 95^th^ percentiles. The white line marks the median of the distribution.](thnov07p2914g003){#F3}

![**Association of Gene Alterations and Smoking.** (A) Three somatic mutational signatures present in the cohort. X-axis consists of adjacent nucleotides to the mutated base indicated on top of each column. Y-axis describes strength of contribution for a given triplet formed of altered base and adjacent nucleotides. (B) Contribution of each signature to smoking categories. (C) Significant smoking related alterations in DNA damage repair (DDR) and chromatin remodeling (CR) genes defined by the Cochran-Mantel-Haenzel test. (D) Validation for the smoking associated mutations in TCGA data. The validation dataset consists of 675 current smokers, 1351 former smokers and 795 never smokers. (E) Significant association between high tumor clonality and smoking. \* (p \< 0.05), \*\* (p \< 0.01)](thnov07p2914g004){#F4}

![**Association of Mutations with AA Population. (**A) Mutational landscape in AA cancers, 30 most frequently mutated genes. (B) Mutation frequencies among Caucasian and AA for significant race-associated genes. (C) Validation of *TP53* mutation in AA in TCGA data. (D) Most common copy number alterations in AA. Genes with significant difference after adjustment are marked with asterisk. (E) Genes with significant connection between race and alteration status validated TCGA data are marked with asterisk \* (p \< 0.05), \*\* (p \< 0.01), \*\*\* (p \<0.001).](thnov07p2914g005){#F5}

###### 

Demographics of patients (N = 431) in the Precision Oncology Initiative

  Characteristic                        No. (%)
  ------------------------------------- ------------
  SMOKING HISTORY                       
  Current                               127 (29.5)
  Former                                145 (33.6)
  Never                                 159 (36.9)
  RACE                                  
  White or Caucasian                    356 (82.6)
  Black or African American             58 (13.5)
  American Indian or Alaska Native      2 (0.5)
  Asian                                 5 (1.2)
  Native Hawaiian or Pacific Islander   1 (0.2)
  Other                                 9 (2.1)
  ETHNICITY                             
  Hispanic or Latino                    8 (1.9)
  Not Hispanic or Latino                423 (98.1)
  CANCER STATUS                         
  Metastasis                            185 (42.9)
  Primary                               220 (51.0)
  Unknown                               26 (6.0)
  DISEASE STAGE                         
  Stage 0                               2 (0.5)
  Stage 1                               31 (7.2)
  Stage 2                               36 (8.4)
  Stage 3                               85 (19.7)
  Stage 4                               231 (53.6)
  Undetermined/Unknown                  46 (10.7)
  TUMOR TYPE                            
  Lung                                  90 (20.9)
  Colorectal                            56 (13.0)
  Other                                 43 (10.0)
  Cup                                   41 (9.5)
  Brain                                 31 (7.2)
  Sarcoma                               30 (7.0)
  Head/Neck                             26 (6.0)
  Other GI                              21 (4.9)
  Breast                                18 (4.2)
  Bladder                               16 (3.7)
  Pancreas                              16 (3.7)
  Ovary/Uterus                          14 (3.2)
  Appendix                              10 (2.3)
  Kidney                                10 (2.3)
  Prostate                              9 (2.1)
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